cell and gene therapy
R&D/ Views & Analysis/ Views and analysis
Gene editing: beyond the hype
George Underwood
CAR, CAR-Tregs, cell and gene therapy, cell therapy, CRISPR, gene editing, gene therapy, JP Morgan, Sangamo
0 Comment
Bayer buys cell & gene therapy firm AskBio for $4 billion
George Underwood
AskBio, Asklepios BioPharmaceutical, Bayer, cell and gene therapy, cell therapy, gene therapy, M&A
0 Comment
Market Access/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis
Preparing for an influx of cell and gene therapy approvals
mike.hammerton@pharmaphorum.com
CAR T, cell and gene therapy, cell therapy, gene therapy
0 Comment
News/ News/ News/ Oncology/ R&D/ Top stories
UK accounts for 12% of cell and gene therapy trials – report
Richard Staines
cell and gene therapy, Oncology, R&D
0 Comment
R&D/ Views & Analysis/ Views and analysis
Will cell and gene therapies disrupt reimbursement?
Dominic Tyer
cell and gene therapy, cell therapy, Deep Dive: Disruptive Technologies, gene therapy, Kymriah, Luxturna, PhRMA, Yescarta
0 Comment
News/ News/ R&D/ R&D/ Top stories
Spectacular results for bluebird’s gene therapy in thalassemia
Andrew McConaghie
bluebird bio, cell and gene therapy
0 Comment
Oncology/ R&D/ Views & Analysis/ Views and analysis
Kite and Sangamo come together in $3bn cancer gene editing alliance
Andrew McConaghie
cell and gene therapy, gene editing, Gilead, Kite, Sangamo
0 Comment
Cancer/ News/ R&D/ Top stories
Novartis snaps up ex-US partnership with Spark on gene therapy
Andrew McConaghie
cell and gene therapy, Luxturna, Novartis, Spark Therapeutics
0 Comment